The average price of tea in 2011 was 2.85 US dollars per kilogram, and it will continue to strengthen in 2012. This is mainly due to the rapid increase in per capita income of China, India and other emerging economies, which has increased tea consumption. The latest data shows that in 2010, global tea consumption increased by 5.6% to 4 million tons. The total consumption of tea in China increased by 1.4% in 2010 to 1.06 million tons, becoming the world's largest consumer of tea. India's tea consumption in 2010 increased by 1% to 830,000 tons.
As tea demand grows, so does production. Global tea production in 2010 increased by 4.2% to 4.1 million tons. Due to the high price, black tea production increased by 5.5% and green tea production increased by 1.9%. China continues to maintain its status as the world's largest tea producer with a production of 1.4 million tons and a share of 33% of the world total.
Looking into the next decade, it is estimated that the world’s black tea production will increase by nearly 1.9% year-on-year, and it will reach 3.28 million tons in 2021, and the price will drop slightly to 2.75 US dollars per kilogram. At the same time, the growth rate of world green tea production is estimated at 7.2%, and it is expected to reach 2.6 million tons by 2021.
Intermediates of Cladribine, Carvedilol, Lurasidone, olmesartan, Risedronate Sodium, Atazanavir, Saxagliptin, Dabigatran,Dapoxetine,Cefixime,Ceftaroline fosamil and etc.
In the short span of time, we have emerged as most promising pharmaceutical intermediates manufacturers, chemical intermediates and bulk drug intermediates suppliers. Our consistent supply, quality products and dedication towards clients have opened up many international avenues for our growth.
In addition, the company also can follow the customer's product needs custom synthesis services
MAIN API PRODUCTS USP/BP
|
PRODUCT NAME |
CAS NUMBER |
SPEVIFICATION |
|
Azithromycin |
117772-70-0 |
BEP |
|
Cefpirome Sulphate sterile |
84957-29-9 |
USP JP16 |
|
Ceftriaxone Sodium (Sterile) |
104376-79-6 |
USP31 |
|
Cefotaxime |
64485-93-4 |
USP30 |
|
Ciprofloxacin HCL |
85721-33-1 |
USP/BP |
|
Gentamicin sulphate |
1405-41-0 |
BP |
|
Levofloxacin |
100986-85-4 |
USP27 |
|
Lincomycin Hydrochloride |
859-18-7 |
EP6.0 |
|
Moxifloxacin Hydrochloride |
186826-86-8 |
USP31 |
|
Tigecycline |
220620-09-7 |
USP |
|
Linezolid |
165800-03-3 |
EP |
|
Dexamethasone |
50-02-2 |
USP/BP/EP |
|
Methylprednisolone |
83-43-2 |
USP/BP/EP |
|
Dexketoprofen trometamol |
156604-79-4 |
BP2008 |
|
Ibuprofen |
15687-27-1 |
BP |
|
Metamizol |
68-89-3 |
DAB |
|
Sulindac |
38194-50-2 |
USP/BP/EP |
|
Naproxcinod |
163133-43-5 |
USP28 |
|
Tripelennamine Hydrochloride |
154-69-8 |
USP28 |
|
Itraconazole |
84625-61-6 |
USP/BP |
|
Cytarabine |
147-94-4 |
USP31 |
|
Leucovorin Calcium |
1492-18-8 |
USP32 |
|
Valsartan |
137862-53-4 |
USP30 |
|
Telmisartan |
144701-48-4 |
USP31 |
|
Rosuvastatin Calcium |
147098-20-2 |
USP/BP |
|
Pitavastatin Calcium |
147526-32-7 |
USP/BP |
|
Fluvastatin |
93957-54-1 |
USP31 |
|
Vinpocetine |
42971-09-5 |
EP6.0 |
|
Atazanavir |
198904-31-3 |
BP |
|
Rosiglitazone |
122320-73-4 |
USP30 |
|
Esomeprazole Magnesium |
161973-10-0 |
USP/BP |
|
Topiramate |
97240-79-4 |
USP31 |
|
Fexofenadine HCl |
153439-40-8 |
Inhouse |
|
Bosentan |
147536-97-8 |
Inhouse |
|
D-Cysteine |
921-01-7 |
Inhouse |
|
D-Phenylalanine |
673-06-3 |
Inhouse |
|
Linagliptin |
668270-12-0 |
Inhouse |
|
Rivaroxaban |
366789-02-8 |
USP |
|
Saxagliptin |
361442-04-8 |
USP |
|
Vildagliptin |
274901-16-5 |
USP |
Major Pharmaceutical Intermediates
| Items Descripation | Structure | Application |
|
MICA ESTER CAS No: 246035-38-1 Purity: ≥98% |
 |
For Cefixime |
|
EHATA CAS No: 64485-82-1 Purity: ≥98% |
 |
For Ceftazidine |
|
2-Chloroadenine CAS No: 1839-18-5 |
 |
For Cladribine, Fludarabine et al |
|
Bicyclo(2,2,1)Heptane-2,3-di-exo-carboximide CAS No: 14805o-29-9 |
 |
For Lurasidne |
|
(R,R)-1,2-Bis(methanesulfonyloxy methyl)Cyclohexane CAS No: 186204-35-3 |
 |
For Lurasidone |
|
3-(Piperazin-1-yl)benzol[d] isothiazole CAS No: 87691-87-0 |
 |
For Lurasidone |
|
Trityl olmesartan CAS No: 144690-92-6 Purity: ≥98% |
|
For olmesartan |
|
3-Acetyl Pyridine CAS No: 350-03-8 |
|
For Risedronate Sodium |
|
3-(AceticAcid)pyridine HCL CAS No: 6419-36-9 |
 |
For Risedronate Sodium |
|
Risedronic Acid CAS No: 105462-24-6 |
 |
For Risedronate Sodium |
|
3-Hydroxy-1-adamantyl-D-Glycine CAS No: 709031-29-8 |
 |
For Saxagliptin |
|
(1s,3s,5s)-3-(aminocarbonyl)-2-azabicyclo(3,1,0) hexane-2-carboxylic acid tert-butyl ester CAS No: 361440-67-7 |
 |
For Saxagliptin |
|
(S)-N-Boc-3- hydroxy-adamantylglycine CAS No: 361442-00-4 |
 |
For Saxagliptin |
|
2-Azabicyclo[3.1.0] hexane-3-carbonitrile, (1s,3s,5s)- CAS No: 866083-42-3 |
 |
For Saxagliptin |
|
Ethyl 3-(pyridin-2-ylamino) propanoate CAS No: 103041-38-9 |
 |
For Dabigatran |
|
N-(4-Cyanophenyl) glycine CAS No: 42288-26-6 |
 |
For Dabigatran |
|
4-methylamino-3-nitrobenzoic Acid CAS No: 41263-74-5 |
 |
For Dabigatran |
|
S-3-Amino-3-phenylpropanoic acid ethyl ester HCL CAS No: 167834-24-4 |
 |
For Dapoxetine |
|
(S)-3-Amino-3-Phemylpropan -1-ol CAS No: 82769-76-4 |
|
For Dapoxetine |
|
(S)-3-Dimethylamino-3-Phemylpropanol CAS No: 82769-75-3 |
|
For Dapoxetine |
|
4-{4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-butynil}-α,α-dimethyl benzene acetic acid CAS No: 832088-68-3 |
For Fexofenadine HCl | |
|
Methyl 2-(4-(4-chlorobutanoyl)phenyl)-2-methylpropanoate CAS No:154477-54-0 |
|
For Fexofenadine HCl |
|
5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone CAS No 461432-22-4 |
|
For Dapagliflozin |
|
4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether CAS No :461432-23-5 |
|
For Dapagliflozin |
Mica Ester,Pharma Intermediates,Ciprofloxacin Hcl Uses,Active Pharmaceutical Ingredients
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.pharma-voice.com